Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making - Report - MDSpire

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making

  • By

  • Eva Compérat

  • Gunhild von Amsberg

  • Lynda Corrigan

  • Stephen P. Finn

  • Glen Kristiansen

  • Angelo Minucci

  • David Olmos

  • Guilhem Roubaud

  • July 1, 2026

  • 0 min

Share

Clinical Report: Homologous Recombination Repair and Genetic Testing in Prostate Cancer

Background

Prostate cancer is the most diagnosed cancer among men and a leading cause of cancer-related mortality in the EU. Approximately 12% of metastatic PCa patients have BRCA1/BRCA2 mutations, which are linked to poorer prognosis and increased sensitivity to targeted therapies. Early identification through HRR and BRCA testing is crucial.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

  • Nearly 25% of patients with metastatic PCa have HRR pathway mutations.
  • About 12% of these mutations involve BRCA1 or BRCA2 genes.
  • Barriers to testing include unequal access and unclear guidelines on testing protocols.

Clinical Implications

Healthcare professionals should be aware of the importance of HRR and BRCA testing in metastatic PCa patients.

Conclusion

The integration of HRR and BRCA testing into clinical practice is important for treatment outcomes in metastatic prostate cancer.

Related Resources & Content

  1. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology, 2025 -- ASCO Guideline
  2. Best Practice Recommendations for Clinical Homologous Recombination Deficiency Testing, The ASCO Post, 2025 -- Best Practice Recommendations
  3. Olaparib for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine, 2019 -- Olaparib Study
  4. the pathologist — ASCO 2026: Genomics Reveal HRD–Treatment Response Link
  5. The ASCO Post — Expert Point of View: George Sledge, MD
  6. Prevalence of BRCA1/2 and HRR Gene Mutations in Patients with Primary and Metastatic Castration-Resistant Prostate Cancer: Insights from Real-World Data
  7. ASCO 2026: Genomics Reveal HRD–Treatment Response Link
  8. Expert Point of View: George Sledge, MD
  9. Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology
  10. Olaparib for Metastatic Castration-Resistant Prostate Cancer | New England Journal of Medicine
  11. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) - ScienceDirect

Original Source(s)

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making

  • by Eva Compérat, Gunhild von Amsberg, Lynda Corrigan, Stephen P. Finn, Glen Kristiansen, Angelo Minucci, David Olmos, Guilhem Roubaud

  • July 1, 2026

Related Content

Clinicopathological and molecular characteristics of primary pulmonary choriocarcinoma: a case report and systematic review

Pagetoid reticulosis (Woringer–Kolopp disease) mimicking eczema: a case report with immunophenotypic analysis and literature review

Case Report: Synchronous minute intramucosal Epstein–Barr virus-associated gastric cancer revealed after short-term Helicobacter pylori eradication